Location History:
- Nishinomiya, JP (2002 - 2006)
- Osaka, JP (2013 - 2016)
- Kanagawa, JP (2016 - 2023)
Company Filing History:
14 out of 1,179 
4 out of 1,858 
Years Active: 2002-2023
Title: Innovations of Tomohiro Kaku: A Pioneer in Heterocyclic Compounds
Introduction
Tomohiro Kaku, an innovative researcher based in Kanagawa, Japan, has made significant contributions to the field of pharmaceuticals through his work on heterocyclic compounds. With a total of 18 patents to his name, Kaku's inventions are paving the way for new therapeutic agents to combat various neurological disorders.
Latest Patents
Among his latest inventions is a heterocyclic compound designed to antagonize NMDA receptors containing the NR2B subunit. This compound is anticipated to serve as a prophylactic or therapeutic agent for disorders such as major depression, bipolar disorder, migraines, pain, and the peripheral symptoms of dementia. The compound is represented by a specific formula, detailed in his patent, allowing for various derivatives and salts.
Career Highlights
Tomohiro Kaku has worked with prominent organizations, including Takeda Pharmaceutical Company Limited and Takeda Chemical Industries, Inc. His tenure at these companies has significantly enriched his expertise in pharmaceutical research and development, further strengthening his portfolio of inventions and patents.
Collaborations
Kaku's innovative journey has also seen him collaborate with esteemed colleagues such as Mitsuhiro Ito and Shigemitsu Matsumoto. These collaborations have fostered a dynamic exchange of ideas, enhancing the scope and impact of their collective research efforts.
Conclusion
Tomohiro Kaku's dedication to advancing medical therapies through his innovative creations in heterocyclic compounds positions him as a leading figure in pharmaceutical research. His contributions not only reflect his commitment to improving healthcare but also demonstrate the significant role of inventors in shaping the future of medicine.